Lundbeck presents new real-world data highlighting meaningful improvements in patients severely impacted by migraine initiating Vyepti® (eptinezumab), at HCOP Annual Conference
PR Newswire —
New six-month results from the Vyepti® (eptinezumab) 12-month, real-world INFUSE study presented at the 2026 Headache Cooperative of the Pacific (HCOP) Annual Conference, Ojai, California1 The INFUSE study includes adults with migraine who had failed at least one preventive...